Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia | Zendy

John C. Byrd | Zendy; Bonnie K. Harrington | Zendy; Susan O’Brien | Zendy; Jeffrey A. Jones | Zendy; Anna Schuh | Zendy; Stephen Devereux | Zendy; Jorge Chaves | Zendy; William G. Wierda | Zendy; Farrukh T. Awan | Zendy; Jennifer R. Brown | Zendy; Peter Hillmen | Zendy; Deborah M. Stephens | Zendy; Paolo Ghia | Zendy; Jacqueline C. Barrientos | Zendy; John M. Pagel | Zendy; Jennifer A. Woyach | Zendy; Dave Johnson | Zendy; Jane Huang | Zendy; Xiaolin Wang | Zendy; Allard Kaptein | Zendy; Brian J. Lannutti | Zendy; Todd Covey | Zendy; Maria Fardis | Zendy; Jesse McGreivy | Zendy; Ahmed Hamdy | Zendy; Wayne Rothbaum | Zendy; Raquel Izumi | Zendy; Thomas G. Diacovo | Zendy; Amy J. Johnson | Zendy; Richard R. Furman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

Author(s) -

John C. Byrd,

Bonnie K. Harrington,

Susan O’Brien,

Jeffrey A. Jones,

Anna Schuh,

Stephen Devereux,

Jorge Chaves,

William G. Wierda,

Farrukh T. Awan,

Jennifer R. Brown,

Peter Hillmen,

Deborah M. Stephens,

Paolo Ghia,

Jacqueline C. Barrientos,

John M. Pagel,

Jennifer A. Woyach,

Dave Johnson,

Jane Huang,

Xiaolin Wang,

Allard Kaptein,

Brian J. Lannutti,

Todd Covey,

Maria Fardis,

Jesse McGreivy,

Ahmed Hamdy,

Wayne Rothbaum,

Raquel Izumi,

Thomas G. Diacovo,

Amy J. Johnson,

Richard R. Furman

Publication year - 2015

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1509981

Subject(s) - bruton's tyrosine kinase , ibrutinib , chronic lymphocytic leukemia , medicine , tyrosine kinase , lymphocytic infiltration , cancer research , leukemia , immunology , pharmacology , receptor

Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL). However, ibrutinib also irreversibly inhibits alternative kinase targets, which potentially compromises its therapeutic index. Acalabrutinib (ACP-196) is a more selective, irreversible BTK inhibitor that is specifically designed to improve on the safety and efficacy of first-generation BTK inhibitors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research